Background
Introduction
The severity of radiographic joint destruction varies between RA-patients. Much research has been focussed on identifying risk factors for radiographic progression, with the ultimate aim of achieving individualized medicine at disease onset. Well-known risk factors are presence of erosions, presence of RA-related auto-antibodies (rheumatoid factor (RF), anticitrullinated-peptide antibodies (ACPA)) and measures of inflammation (C-reactive protein (CRP), number of swollen joints (SJC)).
MRI measures inflammation sensitively; it allows assessment of bone marrow edema (BME), tenosynovitis and synovitis. Previous studies in wrist and MCP-joints showed that inflammation detected with MRI, especially BME, is a strong predictor for radiographic progression. [1] [2] [3] [4] [5] [6] [7] [8] (Table 1 ) However, none of these studies investigated MRI findings in relation to clinical joint inflammation. We recently studied MRI-inflammation in small joints that were not swollen at physical examination and observed MRI-inflammation in 27%, 66% and 13% of non-swollen MCP, wrist and MTP-joints of early arthritis patients. [9] The identification of these inflamed joints may indicate the added value of MRI. However, the relevance of such subclinical inflammation is supported when it associates with radiographic progression. In this study we therefore investigated whether MRI-detected subclinical inflammation is associated with radiographic progression.
Patients and Methods

Patients
Between August 2010 and February 2012, MRI was performed in 179 early arthritis patients of the Leiden Early Arthritis Clinic, a population-based inception-cohort including patients with confirmed clinical arthritis and symptoms for <2 years. At baseline, questionnaires and 66-SJCs were performed and serum obtained. [10] All patients underwent extremity-MRI at baseline; of these 113 had 1-year follow-up including radiographs. Patients without 1-year follow-up were less often diagnosed with RA (Table 2) . Of the 113 patients studied, 53 fulfilled the 2010-criteria for RA at baseline. During the first year, three-quarters of the patients were treated with conventional DMARDs (Table 3 ). All participants provided written informed consent. The study was approved by the local medical ethics committee.
MRI and radiographs
MR imaging of the hand (wrist and MCP2-5 joints) and forefoot (MTP1-5-joints) was performed within two weeks after inclusion, at the most painful side, or in case of completely symmetric symptoms at the dominant side according to the OMERACT-RAMRIS-protocol. The presence of clinical arthritis at physical examination of the joints that were scanned was not a prerequisite. Two patients were excluded because of contraindications for MR imaging. Patients with impaired renal function or known hypersensitivity or allergic reactions to contrast media were imaged without contrast administration (n=2).
MR imaging was performed on an MSK-extreme 1.5T extremity MR imaging system (GE, Wisconsin, USA) using a 145mm coil for the foot and a 100mm coil for the hand. The patient was positioned in a chair beside the scanner, with the hand or foot fixed in the coil with cushions.
The forefoot was scanned using a T1-weighted fast spin-echo (FSE) sequence in the axial plane with repetition time (TR) of 650 ms, echo time (TE) 17ms, acquisition matrix, 388×288, echo train length (ETL) 2; and a T2-weighted FSE sequence with frequency selective fat saturation in the axial plane (TR/TE 3000/61.8; acquisition matrix 300x224, ETL7). Due to time constraints, imaging of the foot was limited to pre-contrast sequences only.
In the hand, the following sequences were acquired before contrast injection: T1-weighted FSE sequence in the coronal plane (TR/TE 650/17ms; acquisition matrix 388×88; ETL2); T2-weighted FSE sequence with frequency selective fat saturation in the coronal plane (TR/TE 3000/61.8ms; acquisition matrix, 300x224, ETL7). After intravenous injection of gadolinium contrast (gadoteric acid, Guerbet, Paris, France, standard dose of 0.1 mmol/kg) the following sequences were obtained: T1-weighted FSE sequence with frequency selective Field-of-view was 100mm for the hand and 140mm for the foot. Coronal sequences had 18 slices with a slice thickness of 2mm and a slice gap of 0.2mm. All axial sequences had a slice thickness of 3mm and a slice gap of 0.3mm, with 20 slices for the hand and 16 for the foot. Total imaging time was approximately 75 minutes.
Synovitis and BME were scored according to RAMRIS [11] ; tenosynovitis in MCP-joints and wrists was assessed as described elsewhere. [12] Two readers scored the MR-images independently, blinded to clinical data; the mean scores were studied. Within-reader ICCs for the total RAMRIS-score were 0.98 and 0.83; the between-reader ICC 0.82. The total Of the 179 EAC patients with MRI; 113 patients had an radiograph at one year of follow-up and 66 patients not. At patient level medians (IQR) are shown and missing scores were imputed with the median of non-missing MRI scores of the same feature of the patient. The 66 swollen joint count and 68 tender joint count was assessed. † The total exceeds 100% as some patients used several DMARDs in the first year. #Trial medication refers to a double-blind randomized trial in which patients received tocilizumab and/or methotrexate. ∞One patient received anti-TNF early in the disease in the IMPROVED trial and the other patient failed methotrexate, hydroxychloroquine and sulfasalazine and then received anti-TNF after 353 days.
MRI-inflammation was the sum of synovitis, BME and tenosynovitis scores. Subclinical inflammation was defined as inflammation on MRI in clinically non-swollen joints. Radiographs were scored according to the Sharp-van-der-Heijde method (SHS) by one reader in chronological order (ICC baseline SHS 0.86). Radiographic progression was defined as the difference in SHS between year-1 and baseline.
Analyses
First, to replicate previous associations between MRI-inflammation and radiographic progression [1] [2] [3] [4] [5] [6] [7] , analyses were done on patient level using a linear regression model with radiographic progression (continuous variable) as outcome. Univariable and multivariable analyses (adjusting for age, gender, ACPA, RF, CRP-level and 66SJC) for total inflammation and each MRI feature separately, were performed. Joints that could not be completely scored on MRI due to insufficient image-quality (1.1% of all individual scores) were imputed with the median value for that feature across all joints or bones within the same patient. Next, analyses were performed on joint level. To allow comparisons of MRI inflammation and radiographic joint damage at joint level several inflammation features were summed. According to RAMRIS, proximal and distal bones of MCP and MTP joints were scored separately for BME, these were summed per joint. For the wrist, 15 bones were scored for BME; these scores were summed for the wrist score. For MRI synovitis, the scores in the MCP and MTP joints were straightforward, in the wrist three joints (distal radioulnar, radio-carpal and intercarpal joint) were scored and summed to obtain the synovitis score in the wrist. For tenosynovitis in the MCP and wrist joints, the scores of the flexor and extensor sites were summed. Also for the SHS scores at joint level, the scores of erosions and joint space narrowing of the wrist that were assessed according to the Sharp van der Heijde scoring method were summed. Missing MRI-scores were not imputed at joint level. To compare frequencies of subclinical inflammation the continuous MRI-data was dichotomized; joints with a score ≥1 were considered positive. In sensitivity analyses a cut-off ≥2 was evaluated. Joints that progressed ≥1 SHS-point in 1-year were considered to have radiographic progression. SPSS version 20.0 was used; p-values <0.05 were considered significant. Table 3 presents baseline characteristics of early arthritis and RA-patients. First, we evaluated the total MRI-inflammation scores in relation to radiographic progression and observed that both the total score and the individual MRI-features were associated with radiographic progression in early arthritis and RA, independent of known risk factors (p<0.05 except for tenosynovitis in RA, Table 4 ). We herewith replicated previous observations. [ [1] [2] [3] [4] [5] [6] [7] Joints with an increase in SHS of ≥1 were considered to have radiographic progression. The percentages at the right part of the figure represent the absolute risks at radiographic progression in the presence or absence of the MRI feature. Dividing these risks by each other results in the relative risk (RR). These were for any MRI inflammation: RR 5.2 (95%CI 1.9-13.9), BME: RR 4.8 (95%CI 1.7-13.1), synovitis RR 6.1 (95%CI 1.7-18.6) and tenosynovitis RR 6.7 (95%CI 1.4-28.7). As a result of using the higher cut-off score of 2, the number of joints positive for MRI inflammation declined and the data should be interpreted with caution (BME positive joints n=78, synovitis positive joints n=41, tenosynovitis positive joints n=30, total inflammation positive joints n=119).
Results
Total MRI inflammation on patient level
Subclinical MRI inflammation on patient level
When separating patients' total MRI-inflammation scores (mean 13.9±12.0) into the scores obtained in swollen joints and the scores obtained in non-swollen joints, the mean score in swollen joints was 7.2±9.4 and in non-swollen joints 6.6±7.8. This suggests that the cumulative amount of MRI-inflammation in non-swollen joints was comparable to that in swollen joints. We subsequently studied non-swollen joints only. Figure 1 showing the number of joints with subclinical inflammation reveals that most patients had 1-3 subclinical inflamed joints. Comparing the number of subclinical inflamed joints between patients with RA and other diagnoses revealed that RA-patients tended to have more joints with subclinical inflammation (2.3 versus 1.9, p=0.11). Evaluating the different inflammation features separately showed that RA-patients mainly had more joints with subclinical BME (1.6 versus 1.1, p=0.03).
Subclinical inflammation on joint level
Next, we investigated subclinical inflammation at joint level. Of all 1,130 joints studied 932 joints were clinically non-swollen. Of these, 232 (26%) had any subclinical MRIinflammation: 17% of non-swollen joints had BME, 16% synovitis and 21% tenosynovitis (Figure 2 ). Two-percent of the 932 non-swollen joints had radiographic progression during year-1 (compared to 8% of the swollen joints). The non-swollen joints with and without subclinical MRI-inflammation were compared to determine the relative risks (RR) of radiographic progression:4% of non-swollen joints with any MRI-inflammation had radiographic progression versus 1% of the joints without subclinical inflammation (RR 3.5, 95%CI 1.3-9.6). Similar analyses for the individual MRI-inflammation features revealed that BME in non-swollen joints had the highest RR of radiographic progression (RR 5.3, 95%CI 2.0-14.0; 7% versus 1%). For synovitis the RR was 3.4 (95%CI 1.2-9.3; 5% versus 1%). For tenosynovitis the RR was 3.0 (95%CI 0.7-12.7). In the subgroup of RA-patients (n=53), the RRs went into the same direction for synovitis and BME, but the 95%CIs were broad (Figure 3 ). Sensitivity analyses with a higher cut-off to define MRI inflammation revealed similar results (Figure 4) .
Discussion
This study is the first investigating the radiographic outcome of MRI-detected inflammation in clinically non-inflamed joints at disease presentation. We observed that joints with subclinical inflammation, especially with BME, had an increased risk of radiographic progression during the first year. Our observation that the total level of MRI-inflammation (in both swollen and nonswollen joints) was an independent predictor for radiographic progression fits with previous findings. [1] [2] [3] [4] [5] [6] [7] Notably, the effect sizes of BME and synovitis in our study were similar to those of Boyesen et al. (beta 0.04 and 0.06 for BME and 0.11 and 0.12 for synovitis, respectively). [1] Furthermore, our finding that subclinical inflammation at disease onset is associated with radiographic progression is in line with previous findings on subclinical inflammation in RA-patients in clinical remission. [13] [14] [15] [16] [17] This study has several limitations. First, the sample size, particularly of the RA-group, was moderate. Although the effect sizes obtained in the total group and RA-group were similar, the 95%CIs of the estimates in the RA-group were broad. Second, radiographic progression was infrequent (3% of all joints in early arthritis and 4% in RA) and defined as ΔSHS on joint level of ≥1. This concerns a small increase but the radiographs were scored in chronological order which reduced the chance on measurement errors. Up-to-date treatment-strategies will have contributed to the low prevalence of radiographic progression. Furthermore, the frequency of progression was determined on joint level, which is relatively uncommon. To obtain a reference, we also analysed previously SHS-scored unilateral MCP2-5, wrist and MTP1-5 joints of EAC RA-patients included in 1993-1999 and 2000-2006 when different treatment strategies were applied. [10] Here, using the same definition, radiographic progression during year-1 was present in 15% and 9% of joints, suggesting that in the currently studied patients treatment had effectively reduced radiographic progression. Nonetheless, despite radiographic progression being infrequent nowadays, progression was significantly more frequent in joints with subclinical inflammation. This suggests that MRI may be valuable to identify joints with increased risk of progression despite normal physical examination and current treatment-strategies.
This study mainly increases the comprehension of the connection between inflammation and structural damage early in the disease. Whether subclinical MRI-inflammation is relevant to clinical practice remains a question, as rheumatologists treat patients and not joints. Information on subclinical inflamed joints would affect treatment decisions most when patients have few clinically swollen joints. A sub-analysis in patients with ≤2 swollen joints showed a slight tendency towards more progression in the presence of more subclinically inflamed joints (ΔSHS1.4 in case of ≥3 subclinically inflamed joints versus ΔSHS 1.0 in case of ≤2 subclinically inflamed joints). Larger studies are required to ascertain whether information on MRI-inflammation is relevant for clinical practice.
MRI is a sensitive tool and MRI-inflammation has been reported in symptom-free persons. [18] [19] [20] Nevertheless, present data indicate that MRI-detected subclinical inflammation in early arthritis negatively affects radiological outcome.
